COVID-19 THERAPY: COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR
Abstract
Introduction: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) is the virus that causes Coronavirus Disease 2019 (COVID-19), a disease of global concern(1). Remdesivir and favipiravir are antiviral drugs that are considered COVID19 therapy, as described in Indonesia's 3rd COVID-19 Management Guidelines. They have a similar mechanism, specifically by inhibiting RNA dependent RNA polymerase of the virus (3). Several studies have reported that patients who were treated with these antivirals had a shorter hospital stays (46). However, the comparison of efficacy between remdesivir and favipiravir is still unknown.
Methods: An observational analytic study was done using a retrospective cohort design. Eighty-eight medical records of COVID-19 patients between January 2021 to August 2021 are collected by consecutive sampling techniques, and this research was carried out at Gotong Royong Hospital Surabaya.
Results: Based on the statistical analysis test, there was no clinical improvement difference found, neither patients received remdesivir nor favipiravir based on their clinical manifestations, such as ventilation support and chest X-ray, measured by WHO ordinal scale (p=0,486 ; p>0,05 on the first week and p=0,942 ; p>0,05 on the second week).
Conclusions: Improved clinical manifestations were seen in the second week of therapy, either in patients who received remdesivir or favipiravir, but there was no significant effectivity difference between those drugs.
Keywords
Full Text:
PDFReferences
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA - J Am Med Assoc. 2020;324(8):78293.
Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo W, Susilo A, et al. PEDOMAN TATALAKSANA COVID-19. 3rd ed. Jakarta; 2020.
Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front Cell Infect Microbiol. 2020;10(November):117.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 Final Report. N Engl J Med. 2020;383(19):181326.
Spinner CD, Gottlieb RL, Criner GJ, Arribas Lpez JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial. JAMA - J Am Med Assoc. 2020;324(11):104857.
Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, Ebeid FFS, El Ghafar MSA, et al. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Arch Virol [Internet]. 2021;166(3):94954. Available from: https://doi.org/10.1007/s00705-021-04956-9
Situation Report-51 SITUATION IN NUMBERS total and new cases in last 24 hours.
Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinicaltherapeutic staging proposal. J Hear Lung Transplant. 2020;39(5):4057.
Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020 Dec 1;11(1).
Keputusan Menteri Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MenKes/413/2020 Tentang Pedoman Pencegahan dan Pengendalian Corona Virus Disease 2019 (Covid-19). MenKes/413/2020. 2020;2019:207.
Magdalena, Sugiri YJ, Tantular R, Listyoko A. Karakteristik Klinis Pasien COVID-19 di Rumah Sakit Dr. Saiful Anwar, Malang. J Respirologi Indones. 2021;41(1):710.
Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun [Internet]. 2020;11(1):110. Available from: http://dx.doi.org/10.1038/s41467-020-19741-6
Bwire GM. Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? SN Compr Clin Med. 2020;2(7):8746.
Wayne MT, Weng W, OMalley M, Bozyk P, Doshi MM, Flanders SA, et al. Variation in COVID-19 disease severity at hospital admission over time and across hospitals. Medicine (Baltimore). 2021;100(37):e27265.
Certain Medical Conditions and Risk for Severe COVID-19 Illness | CDC [Internet]. [cited 2021 Mar 31]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F 2019-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-risk.html
Hu X, Hu C, Yang Y, Chen J, Zhong P, Wen Y, et al. Clinical characteristics and risk factors for severity of COVID-19 outside Wuhan: a double-center retrospective cohort study of 213 cases in Hunan, China. Ther Adv Respir Dis. 2020;14(April):115.
de Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, de Souza FD, Rodacki M, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr [Internet]. 2020;12:75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32874207%0Ahttp://www.pubmedcentral.nih.gov/a rticlerender.fcgi?artid=PMC7456786
Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Cardiovascular comorbidity and its impact on patients with COVID-19. Eur Respir J. 2020;55(6).
World Health Organization. WHO R&D Blueprint novel COronavirus, COVID-19 Therapeutic Trial Synopsis [Internet]. 2020 [cited 2020 Sep 9]. Available from: https://www.who.int/indonesia/news/novel-coronavirus
Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis [Internet]. 2021;103:6271. Available from: https://doi.org/10.1016/j.ijid.2020.11.142
Zeitlinger M, Koch BCP, Bruggemann R, De Cock P, Felton T, Hites M, et al. Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A ComprehensiveReview by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicr. Clin Pharmacokinet [Internet]. 2020;59(10):1195216. Available from: https://doi.org/10.1007/s40262-020-00924-9
Du YX, Chen XP. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clin Pharmacol Ther. 2020;108(2):2427.
Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and its antiviral activity against COVID-19: A systematic review. Clin Epidemiol Glob Heal [Internet]. 2021;9(July):1237. Available from: https://doi.org/10.1016/j.cegh.2020.07.011
Fujii S, Ibe Y, Ishigo T, Inamura H, Kunimoto Y, Fujiya Y, et al. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients. J Infect Chemother [Internet]. 2021;27(7):10517. Available from: https://doi.org/10.1016/j.jiac.2021.04.013
Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med. 2021;385(15):135571.
ODriscoll B, Howard L, Earis J, Mak V, Bajwah S, Beasley R, et al. BTS guidelines for oxygen use in healthcare. Thorax. 2017;72(June):435.
DOI: https://doi.org/10.33508/jwmj.v4i4.4344
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Widya Medika Junior is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License